CMS
Biocept HER2 Assay Gains Coverage Under Medicare Local Coverage Determination for CTC Tests
Under the LCD, CTC assays, such as Biocept's, will now be covered to guide targeted treatment decisions for patients with breast and other cancers under certain circumstances.
The commission validated industry complaints about price data collection practices but suggested more action might be needed to control costs.
Veracyte Bladder Cancer Test Receives Medicare Coverage
The patient must be a candidate for multiple potential treatments with varying levels of intensity or multiple therapies.
The proposed change would delete payable cancer codes if they contain the word "unspecified" even if the word is included in a code that doesn't impact coverage.
Palmetto Releases Draft LCD for Prostate Cancer Risk Stratification Tests
Under the local coverage determination, tests to help identify patients who may benefit from a prostate biopsy would be covered under certain conditions.